Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 387

1.

Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.

Miller A, Spada V, Beerkircher D, Kreitman RR.

Mult Scler. 2008 May;14(4):494-9. doi: 10.1177/1352458507085029. Epub 2008 Jan 21.

PMID:
18208875
2.

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

Zwibel HL; Copolymer-1 Treatment Study Principal Investigators.

Acta Neurol Scand. 2006 Jun;113(6):378-86.

PMID:
16674604
3.

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.

Clin Ther. 2010 Jun;32(6):1061-6. doi: 10.1016/j.clinthera.2010.06.005.

PMID:
20637960
4.

Long-term follow up of glatiramer acetate compassionate use in Belgium.

Sindic CJ, Seeldrayers P, Vande Gaer L, De Smet E, Nagels G, De Deyn PP, Medaer R, Guillaume D, D'Hooghe MB, Deville MC, Decoo D, Sadzot B, Van Landegem W, Strauven T, Pepin J, Merckx H, Caekebeke J, van der Tool MA.

Acta Neurol Belg. 2005 Jun;105(2):81-5.

PMID:
16076061
5.

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.

Johnson KP, Ford CC, Lisak RP, Wolinsky JS.

Acta Neurol Scand. 2005 Jan;111(1):42-7.

PMID:
15595937
6.

[Long-term effects of glatiramer acetate in multiple sclerosis].

Brochet B.

Rev Neurol (Paris). 2008 Nov;164(11):917-26. doi: 10.1016/j.neurol.2008.02.045. Epub 2008 May 16. French.

PMID:
18790510
7.
8.

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K.

Appl Health Econ Health Policy. 2009;7(2):91-108. doi: 10.2165/11314900-000000000-00000.

PMID:
19731967
10.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
11.

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.

Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.

Mult Scler. 2008 Jun;14(5):663-70. doi: 10.1177/1352458507085759. Epub 2008 Apr 18.

PMID:
18424479
12.

[Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].

Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Edan G.

Rev Neurol (Paris). 2006 Feb;162(2):185-94. French.

PMID:
16518258
13.

[Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].

Gaillard N, Fabro-Perray P, Faillie JL, Le Bayon A, Castelnovo G, Dupeyron A, Froger J, Pelissier J, Labauge P.

Rev Neurol (Paris). 2007 Jan;163(1):72-81. French.

PMID:
17304175
14.
15.

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.

Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS; Copaxone Study Group.

Mult Scler. 2006 Jun;12(3):309-20.

PMID:
16764344
16.

[Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].

Mesaros S, Stojsavljević N, Dujmović I, Mandić E, Drulović J.

Srp Arh Celok Lek. 2004 Jul-Aug;132(7-8):209-13. Serbian.

17.

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus H, Wolinsky J.

Mult Scler. 2010 Mar;16(3):342-50. doi: 10.1177/1352458509358088. Epub 2010 Jan 27.

18.

[Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].

Mezei Z, Bereczki D, Csiba L, Csépány T.

Ideggyogy Sz. 2006 Nov 20;59(11-12):442-7. Hungarian.

PMID:
17203882
19.

[Application of the Multiple Sclerosis Functional Composite in Debrecen].

Mezei Z, Bereczki D, Csiba L, Csépány T.

Ideggyogy Sz. 2005 Mar 20;58(3-4):113-8. Hungarian.

PMID:
15887414
20.

Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.

Healy BC, Engler D, Gholipour T, Weiner H, Bakshi R, Chitnis T.

J Neurol Sci. 2011 Apr 15;303(1-2):109-13. doi: 10.1016/j.jns.2010.12.024. Epub 2011 Jan 19.

PMID:
21251671

Supplemental Content

Support Center